The National Bank for Economic and Social Development (BNDES) has recorded record figures in credit approvals for the Brazilian pharmaceutical and pharmachemical industries. According to data released by the financial institution this Thursday (18), R$2 billion has been released since the beginning of 2024. In just 6 months, this is already the highest amount recorded in a single year since 1995.
“The amounts approved in 2024 are 32% higher than the entire year of 2023 (R$ 1.4 billion) and correspond to 16% of the total 30 years of BNDES support for the segment. With the bank’s support, industries are developing new medicines, new pharmaceutical associations (which facilitate absorption and administration), vaccines, setting up research and development centers and acquiring machinery and equipment”, states a note released by BNDES.
According to BNDES, the increase in approvals is related to the resumption of investments in strategic industrial sectors. In January of this year, the federal government launched the New Industry Program (NIB).
The goal of the program is to stimulate the productive sector to promote the country’s development and reverse the scenario of deindustrialization, according to the federal government. The NIB involves the articulation of several State instruments, such as special credit lines, non-reimbursable resources, regulatory and intellectual property actions, in addition to a public works and procurement policy.
